Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer.

Journal: Surgical oncology
PMID:

Abstract

OBJECTIVES: To test contemporary rates and predictors of open conversion at minimally invasive partial nephrectomy (MIPN: laparoscopic or robotic partial nephrectomy).

Authors

  • Stefano Luzzago
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Giuseppe Rosiello
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Angela Pecoraro
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Marina Deuker
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Franziska Stolzenbach
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Francesco Alessandro Mistretta
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Zhe Tian
    Sami-Ramzi Leyh-Bannurah, Dirk Pehrke, Hartwig Huland, Markus Graefen, and Lars Budäus, Prostate Cancer Center Hamburg-Eppendorf; Sami-Ramzi Leyh-Bannurah, Margit Fisch, and Guido Sauter, University Medical Center Hamburg-Eppendorf, Hamburg; Ulrich Wolffgang, University of Muenster, Muenster, Germany; and Zhe Tian and Pierre I. Karakiewicz, University of Montreal Health Center, Montreal, Canada.
  • Gennaro Musi
    Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Emanuele Montanari
    Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Shahrokh F Shariat
    Department of Urology, Medical University of Vienna and General Hospital, Vienna, Austria.
  • Fred Saad
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Alberto Briganti
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Ottavio De Cobelli
    Department of Urology, European Institute of Oncology (IEO), Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
  • Pierre I Karakiewicz
    Sami-Ramzi Leyh-Bannurah, Dirk Pehrke, Hartwig Huland, Markus Graefen, and Lars Budäus, Prostate Cancer Center Hamburg-Eppendorf; Sami-Ramzi Leyh-Bannurah, Margit Fisch, and Guido Sauter, University Medical Center Hamburg-Eppendorf, Hamburg; Ulrich Wolffgang, University of Muenster, Muenster, Germany; and Zhe Tian and Pierre I. Karakiewicz, University of Montreal Health Center, Montreal, Canada.